Metabolomic Impacts of Branched-chain Amino Acid Supplementation During Endurance Exercise
Public ClinicalTrials.gov record NCT04969536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall goal of this investigation was to determine the impact of branch-chained amino acids (BCAAs) supplementation on serotonin and associated metabolites during endurance exercise on healthy individuals. Specifically, despite the strong theoretical basis for supplementation of BCAAs to attenuate serotonin production and fatigue during exercise, most human clinical trials have failed to demonstrate these benefits. To shed light on this discrepancy, the purpose of this study was to measure the impact of BCAA supplementation on serotonin and associated metabolites during exercise. To achieve this purpose, investigators determined the effects of the consumption of a BCAA beverage on endurance exercise performance and serum metabolites. The supplementation protocol consisted of two trials in which each participant consumed 8 grams of BCAA supplement in a beverage or a placebo in randomized order. It was hypothesized that post-exercise metabolites would differ between BCAA and placebo conditions.
Study identification
- NCT ID
- NCT04969536
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- Branched Chain Amino Acids Dietary Supplement
- Placebo Other
Dietary Supplement · Other
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2019
- Primary completion
- Feb 22, 2021
- Completion
- Feb 22, 2021
- Last update posted
- May 2, 2023
2019 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Montana State University | Bozeman | Montana | 59717 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04969536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2023 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04969536 live on ClinicalTrials.gov.